NOT FOR DISTRIBUTION
Header cover image

Dar Al Dawa Development and Investment

Market Cap

د.أ43.8m

Last Updated

2021/09/20 15:28 UTC

Data Sources

Company Financials

Executive Summary

Dar Al Dawa Development and Investment Co. More Details


Snowflake Analysis

Fair value with questionable track record.

Share Price & News

How has Dar Al Dawa Development and Investment's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: DADI is less volatile than 75% of JO stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: DADI's weekly volatility (2%) has been stable over the past year.


Market Performance


7 Day Return

-3.8%

DADI

-0.2%

JO Pharmaceuticals

-0.1%

JO Market


1 Year Return

11.6%

DADI

-5.1%

JO Pharmaceuticals

36.3%

JO Market

Return vs Industry: DADI exceeded the JO Pharmaceuticals industry which returned -5.1% over the past year.

Return vs Market: DADI underperformed the JO Market which returned 36.3% over the past year.


Shareholder returns

DADIIndustryMarket
7 Day-3.8%-0.2%-0.1%
30 Day-12.0%2.4%2.4%
90 Day-10.7%-5.8%-5.3%
1 Year15.9%11.6%-3.9%-5.1%40.4%36.3%
3 Year7.3%3.3%29.4%23.0%11.2%0.6%
5 Year-38.2%-43.2%35.6%25.3%17.6%-2.8%

Long-Term Price Volatility Vs. Market

How volatile is Dar Al Dawa Development and Investment's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Dar Al Dawa Development and Investment undervalued compared to its fair value and its price relative to the market?

4.19x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: DADI (JOD1.25) is trading above our estimate of fair value (JOD0.1)

Significantly Below Fair Value: DADI is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: DADI is good value based on its PE Ratio (4.2x) compared to the Asian Pharmaceuticals industry average (25x).

PE vs Market: DADI is good value based on its PE Ratio (4.2x) compared to the JO market (13.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DADI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DADI is good value based on its PB Ratio (1.1x) compared to the XA Pharmaceuticals industry average (2.4x).


Future Growth

How is Dar Al Dawa Development and Investment forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.3%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Dar Al Dawa Development and Investment has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Dar Al Dawa Development and Investment performed over the past 5 years?

5.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DADI has a large one-off gain of JOD8.3M impacting its June 30 2021 financial results.

Growing Profit Margin: DADI became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: DADI has become profitable over the past 5 years, growing earnings by 5.3% per year.

Accelerating Growth: DADI has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: DADI has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.9%).


Return on Equity

High ROE: Whilst DADI's Return on Equity (24.34%) is high, this metric is skewed due to their high level of debt.


Financial Health

How is Dar Al Dawa Development and Investment's financial position?


Financial Position Analysis

Short Term Liabilities: DADI's short term assets (JOD61.9M) exceed its short term liabilities (JOD54.8M).

Long Term Liabilities: DADI's short term assets (JOD61.9M) exceed its long term liabilities (JOD8.8M).


Debt to Equity History and Analysis

Debt Level: DADI's debt to equity ratio (105.9%) is considered high.

Reducing Debt: DADI's debt to equity ratio has increased from 50.4% to 105.9% over the past 5 years.

Debt Coverage: DADI's debt is not well covered by operating cash flow (9.2%).

Interest Coverage: DADI's interest payments on its debt are not well covered by EBIT (1.8x coverage).


Balance Sheet


Dividend

What is Dar Al Dawa Development and Investment current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DADI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DADI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DADI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DADI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: DADI is not paying a notable dividend for the JO market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DADI's dividend in 3 years as they are not forecast to pay a notable one for the JO market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Maen Abdelhafez (48 yo)

2.42yrs

Tenure

Dr. Maen Abdelhafez serves as Chief Executive Officer at Dar Al Dawa Development and Investment Co. Ltd. since April 07, 2019. He holds a bachelor's degree in pharmacy from the University of Jordan in 1995...


Leadership Team

Experienced Management: DADI's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: DADI's board of directors are considered experienced (3.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 40%.


Top Shareholders

Company Information

Dar Al Dawa Development and Investment Co. Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Dar Al Dawa Development and Investment Co. Ltd.
  • Ticker: DADI
  • Exchange: ASE
  • Founded: 1975
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: د.أ43.750m
  • Shares outstanding: 35.00m
  • Website: https://www.dadgroup.com

Number of Employees


Location

  • Dar Al Dawa Development and Investment Co. Ltd.
  • PO Box 9364
  • Amman
  • 11191
  • Jordan

Listings


Biography

Dar Al Dawa Development and Investment Co. Ltd., an integrated pharmaceutical company, develops, produces, markets, and commercializes medicines and wellness consumer products. The company offers products...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/20 15:28
End of Day Share Price2021/09/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.